Skip to main content
Signal8

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

$JAGXPress releaseMay 6, 2026, 9:00 AM ETRead the release

Jaguar Health announced preliminary discussions with the FDA to evaluate a Breakthrough Therapy Designation for crofelemer to treat pediatric Microvillus Inclusion Disease. The filing is supported by data from two patients showing meaningful reductions in weekly parenteral support needs, with a pivotal randomized trial having completed enrollment.

Key figures

Drug Name
crofelemer
Phase Of Trial
pivotal randomized double-blind placebo-controlled
Patients in poc
2
Current patient penetration
4% of estimated living pediatric MVID patients

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.